ACADIA PHARMACEUTICALS INC (ACAD) earnings date
Feb 24, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-20
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Nov 4, 2026 | after close | 35 | 8-K |
| Q2 FY2026 | Tue, Aug 4, 2026 | after close | 35 | 8-K |
| Q1 FY2026 | Wed, May 6, 2026 | after close | 36 | 8-K |
| Q4 FY2025 | Wed, Feb 25, 2026 | after close | 56 | 8-K |
| Q3 FY2025 | Wed, Nov 5, 2025 | after close | 36 | 8-K |
| Q2 FY2025 | Wed, Aug 6, 2025 | after close | 37 | 8-K |
| Q1 FY2025 | Wed, May 7, 2025 | after close | 37 | 8-K |
| Q4 FY2024 | Wed, Feb 26, 2025 | after close | 57 | 8-K |
What they guided beta
| Q3 FY2026 | "Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results - Third quarter GAAP total revenues of $342 million, up 22% year-over-year as compared to non-GAAP adjusted total revenues - Third quarter DAYBUE ® GAAP net sales of $140 million, up 39% year-over-year driven by strong uptake of DAYBUE STIX - Third quarter NUPLAZID ® GAAP net sales of $202 million, up 12% year-over-year on a non-GAAP adjusted basis - Raises 2026 DAYBUE net sales guidance to $505–$520 million; narrows NUPLAZID range and total revenue range - Additional data from Phase 3-enabling RADIANT Phase 2 Study to be pre" exhibit |
| Q3 FY2026 | "As we look ahead to 2027, we anticipate two Phase 2 readouts: ACP-211 in major depressive disorder, and remlifanserin in Lewy body dementia psychosis, for which we are providing timing guidance for the first time." exhibit |
| Q3 FY2026 | "Additional data will be presented at the Clinical Trials on Alzheimer’s Disease conference on November 17, 2026, in Boston." exhibit |
| Q3 FY2026 | "Two Phase 2 readouts anticipated in 2027: ACP-211 in major depressive disorder (MDD) in the second half and, for the first time, guidance for remlifanserin in Lewy body dementia Psychosis (LBDP) in the fourth quarter." exhibit |
| Q3 FY2026 | "Full Year 2026 Financial Guidance (GAAP): Acadia is updating its 2026 guidance:" exhibit |
| Q2 FY2026 | "Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results - Second quarter DAYBUE ® GAAP net sales of $125 million, up 30% year-over-year driven by strong uptake of DAYBUE STIX - Second quarter NUPLAZID ® GAAP net sales of $183 million, up 10% year-over-year on a non-GAAP adjusted basis - Increased full year 2026 total revenue guidance to $1.24 to $1.30 billion, reflecting higher DAYBUE guidance of $480 to $510 million and reaffirmed NUPLAZID guidance of $760 to $790 million - Topline results from the Phase 2 remlifanserin study in Alzheimer’s disease psychosis anticipated Septembe" exhibit |
| Q2 FY2026 | "We remain confident that both franchises are on track to achieve our long-term ambition of approximately $1.7 billion in annual net sales in 2028." exhibit |
| Q2 FY2026 | "Completed enrollment in the Phase 2 portion of the RADIANT program evaluating remlifanserin in Alzheimer's disease psychosis and initiated Phase 3 screening and enrollment; topline Phase 2 results are expected in September to October 2026." exhibit |
| Q2 FY2026 | "Full Year 2026 Financial Guidance (GAAP): Acadia is updating its 2026 guidance:" exhibit |
| Q2 FY2026 | "results, and the enrollment of the Phase 3 portion of the RADIANT development program, (v) potential approval of DAYBU (trofinetide) in the European Union, (vi) plans for, including timing, development and progress of commercialization or regulatory timelines for our products and our product candidates; (vii) benefits to be derived from and efficacy of our products, including the potential advantages of our products; and (viii) our estimates regarding our future financial performance, profitability, capital requirements or expenses, including our full year 2026 financial guidance and anticipat" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ACAD
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ACAD
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/ACAD/"><img src="https://veritasdata.dev/embed/ACAD.svg" alt="ACAD earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/ACAD/)
Script
<script async src="https://veritasdata.dev/embed/ACAD.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ACAD"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.